MedTrace Logo

CardioTOxicity Induced by andRogeNICS and Their Antagonists (TORNICS)

NCT03193138 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3096

Last updated 2019-09-25

No results posted yet for this study

Summary

Anti-androgenic therapies relying on peripheral and/or central blockade for the treatment of prostate cancer seems to have an impact on the cardio-vascular system. This study investigates reports of cardiovascular toxicities for treatment including Anatomical Therapeutic Chemical (ATC) classification: sex hormones (G03), hypothalamic hormones (H01C) and sex hormones used in treatment of neoplastic diseases (L02) in the French pharmacovigilance database and European Clinical Trials (EudraCT) database.

Conditions

  • Heart Diseases

Interventions

DRUG

Hormonal therapies: G03, H01C and L02 in the ATC classification

Hormonal therapies including all therapies classified G03, H01C and L02 in the ATC classification

Sponsors & Collaborators

  • Groupe Hospitalier Pitie-Salpetriere

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-07
Primary Completion
2017-06-21
Completion
2017-06-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03193138 on ClinicalTrials.gov